Facing the challenge of refined operations, pharmaceutical companies are actively exploring new models of digital health

At the 5th China International Import Expo, a large number of multinational pharmaceutical companies signed strategic cooperation agreements with Alibaba Health to jointly explore a patient-centered full-link digital medical and health service model to improve the health level and quality of life
of patients.
Among them, on November 6, Alibaba Health and Novartis China signed a strategic cooperation agreement at the 5th China Import Expo, under which the two parties will upgrade their partnership and further deepen digital health cooperation in the fields of "cardiovascular and cerebrovascular, immunological, respiratory, oncology, ophthalmology" and explore the full-link management mode
of patients with their respective advantages 。 It is understood that this cooperation upgrade will give full play to Alibaba Health's capabilities in pharmaceutical retail, smart logistics, digital health management, Internet medical innovation, etc.
, as well as Novartis' accumulated professional knowledge, innovative solutions and international experience, to jointly explore a "patient-centered" Internet medical and health service model and improve the quality of life
of patients.
Pfizer China also signed a strategic cooperation agreement on disease education innovation with Alibaba Health, and the two parties will work together to carry out disease education and help achieve "Healthy China 2030"
.
The two sides announced that through this cooperation, they will jointly explore innovative models of disease education and explore new cooperation paths to strengthen exchanges
.
The two sides will give full play to their advantages in the field of public health, create innovative solutions, and work together to deepen public disease education and enhance public awareness
of diseases.
.
.
.
.
.
.
According to statistics, Alibaba Health has cooperated with thousands of pharmaceutical companies around the world and is actively carrying out digital exploration
.
In fact, with the continuous development of cloud computing, 5G, the Internet, big data and other technologies, the Internet medical process is advancing rapidly, and more and more patients can independently manage their diseases
through online consultation and drug purchase.
At the same time, the cooperation between pharmaceutical companies and digital health platforms is increasing
.
In addition to Ali Health, in April this year, Meituan Pharmacies joined hands with Bayer and NUS Pharmacy to carry out omni-channel integrated marketing, and drug sales increased by 100% year-on-year during the event, and the offline theme pharmacy jointly built by the three parties also achieved a month-on-month growth
of 63%.
It is understood that Meituan has also reached in-depth cooperation
with many domestic and foreign pharmaceutical companies such as China Resources Sanjiu, Harbin Pharmaceutical, Jichuan, Bayer, Johnson & Johnson, GSK, Organon, Pfizer, Hui Zhi and so on.
Industry analysts believe that with the implementation of policies such as the two-invoice system, consistency evaluation, volume procurement, and medical insurance fee control, the drug circulation link has been compressed and the drug price space has been squeezed
.
Gone are the days of high gross margins, pharmaceutical companies are generally facing the challenge of refined operations, so digitalization has begun to play an increasingly important role
in the pharmaceutical industry.
In the future, exploring new models and paths of digital health services and providing patients with inclusive and accessible health management services will become one of the important directions for the development of
pharmaceutical companies.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.